Cantor Fitzgerald Forecasts Strong Price Appreciation for United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics (NASDAQ:UTHR) had its price objective lifted by analysts at Cantor Fitzgerald from $525.00 to $625.00 in a report issued on Thursday, MarketBeat.com reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 16.27% from the stock’s current price.

Several other research analysts have also issued reports on UTHR. UBS Group increased their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. HC Wainwright upped their target price on shares of United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Royal Bank Of Canada increased their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Finally, Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $548.09.

United Therapeutics Trading Down 1.3%

UTHR traded down $7.17 during trading on Thursday, hitting $537.55. The stock had a trading volume of 88,291 shares, compared to its average volume of 420,455. The firm has a market cap of $23.56 billion, a PE ratio of 19.24, a P/E/G ratio of 1.93 and a beta of 0.84. United Therapeutics has a 12 month low of $266.98 and a 12 month high of $548.12. The company has a 50 day simple moving average of $484.97 and a 200-day simple moving average of $458.01.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same period in the previous year, the business posted $6.19 EPS. The company’s revenue for the quarter was up 7.4% on a year-over-year basis. As a group, sell-side analysts anticipate that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $483.16, for a total value of $4,010,228.00. Following the completion of the transaction, the executive vice president directly owned 36,844 shares of the company’s stock, valued at approximately $17,801,547.04. The trade was a 18.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $539.54, for a total transaction of $5,125,630.00. Following the transaction, the chief executive officer owned 130 shares in the company, valued at $70,140.20. The trade was a 98.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 342,947 shares of company stock worth $167,479,373. Corporate insiders own 10.30% of the company’s stock.

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Torren Management LLC bought a new position in shares of United Therapeutics during the 4th quarter valued at about $26,000. Activest Wealth Management lifted its stake in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares in the last quarter. Entrust Financial LLC bought a new position in United Therapeutics in the fourth quarter valued at approximately $31,000. Wilmington Savings Fund Society FSB boosted its holdings in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. bought a new stake in shares of United Therapeutics during the fourth quarter worth $48,000. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.